Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The 2026 Rare Neuroimmune Disorders Symposium spotlighted a landmark trial showing satralizumab cut relapse risk by 68% in MOGAD — potentially the first FDA-approved therapy for the condition. Experts also proposed retiring the century-old term "transverse myelitis" in favor of clearer, etiology-based diagnoses. Patients highlighted mental health support as a critical unmet need.
The Siegel Rare Neuroimmune Association's 2026 symposium brought together patients, families, and clinicians to discuss major advances in rare neuroimmune disorders, including MOGAD, NMOSD, and myelitis. A standout moment was the presentation of the phase 3 METEOROID trial, which found that satralizumab (Enspryng) reduced relapse risk by 68% vs. placebo in MOGAD patients — the first-ever registrational trial for the condition. The FDA has granted priority review to the drug, with a decision expected by January 2027.
On the diagnostic front, experts are pushing to retire the nearly century-old term "transverse myelitis," proposing that patients instead be classified as having "myelitis" tied to a specific cause (like MS or NMOSD) or "idiopathic myelitis." The change aims to reduce confusion for both clinicians and patients, though concerns were raised about impacts on patient identity and insurance coverage. New criteria are expected by 2027.
By the Numbers
Why it matters: These advances signal a turning point for patients with rare neuroimmune disorders — diseases that, just 20 years ago, were barely recognized. A potential first-ever FDA-approved therapy for MOGAD and clearer diagnostic language could meaningfully improve both treatment access and patient outcomes.